

## DAFTAR PUSTAKA

1. J Larry J, Anthony S F, Dennis L K, Stephen L H, Dan L L, Joseph L. Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw Hill Education; 2012.
2. Hermawan AG. Sepsis. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata K SS, editors. Buku Ajar Ilmu Penyakit Dalam jilid I Ed VI. Jakarta: Interna Publishing; 2014.
3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock. *Jama*. 2016;315(8):801–10.
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. *Intensive Care Med*. 2013;39(2):165–228.
5. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014;5(1):1–11.
6. Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis – Current estimates and limitations. 2015. 1-61.
7. Angus D, Linde-Zwirble W, Clermont G, Carcillo J, Pinsky M. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. *Crit Care Med*. 2001;29:1303–10.
8. Bataar O, Lundeg G, Tsenddorj G, Jochberger S, Grander W, Baelani I, et al. Nationwide survey on resource availability for implementing current sepsis guidelines in Mongolia. *Bull World Health Organ*. 2010;88(11):839–46.
9. Menteri Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis. 2017.
10. Zaccone V, Tosoni A, Passaro G, Vincenza C, Impagnatiello M, Donatella D, et al. Sepsis in Internal Medicine wards : current knowledge, uncertainties and new approaches for management optimization. *Ann Med*. 2017;49(7):582–92.
11. Hidayati, Arifin H, Raveinal. Kajian Penggunaan Antibiotik pada Pasien Sepsis dengan Gangguan Ginjal. *J Sains Farm Klin*. 2016;2(2):129–37.

12. Azaria A. Pola Penggunaan Antibiotik Pada Pasien Rawat Inap Penyakit Dalam RSUP Dr. M. Djamil Padang Tahun 2017 (skripsi). Padang: Fakultas Kedokteran Universitas Andalas; 2016
13. Tiru B, DiNino EK, Orenstein A, Mailloux PT, Pesaturo A, Gupta A, et al. The Economic and Humanistic Burden of Severe Sepsis. *Pharmacoeconomics*. 2015;33(9):925–37.
14. Kementerian Kesehatan RI. Penerapan Kajian Farmakoekonomi. 2013.
15. Faridah N, Machlaurin A, Subagijo PB. Analisis Efektivitas Biaya Penggunaan Antibiotik terhadap Pasien Sepsis Pediatrik di Rawat Inap RSD dr . Soebandi Kabupaten Jember pada Tahun 2014. *e-Jurnal Pustaka Kesehat*. 2016;4(2):255–62.
16. Ningsih1 PK, Subagijo PB. Analisis Efektivitas Biaya Penggunaan Antibiotik Pasien Sepsis di Rumah Sakit RSD dr. Soebandi Tahun 2014-2015. *e-Jurnal Pustaka Kesehat*. 2017;5(1):151–6.
17. Utami ER. Antibiotika, Resistensi dan Rasionalitas Terapi. *SAINTIS*. 2012;1:124–38.
18. Goldman MP, Nair R. Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics? *Cleve Clin J Med*. 2007;74(SUPPL.4):38–47.
19. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Vol. 45, *Critical Care Medicine*. 2017. 486-552.
20. Simoens S. Factors Affecting the Cost Effectiveness of Antibiotics. *Chemother Res Pract*. 2011;2011:1–6.
21. Presiden RI. Undang-undang tentang Sistem Jaminan Sosial Nasional. 2004.
22. Kementerian Kesehatan RI. Petunjuk Teknis Sistem Indonesian Case Base Groups (INA-CBGs). 2014.
23. Dumaris H. Analisis Perbedaan Tarif Rumah Sakit dan Tarif INA-CBG ' s Pelayanan Rawat Jalan di RSUD Budhi Asih Jakarta Tahun 2015. *J ARSI*. 2016;3(1):20–8.

24. Purba AKR. Analisis Cost Effectiveness Terapi Antibiotik Empirik pada Pasien Pneumonia Komunitas Rawat Inap di RSUD. Dr. Soetomo, Surabaya (Thesis). Jakarta: Universitas Indonesia; 2015.
25. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. *Intensive Care Med.* 2007;33(4):606–18.
26. Polat G, Ugan RA, Cadirci E, Halici Z. Sepsis and Septic Shock: Current Treatment Strategies and New Approaches. *Eurasian J Med.* 2017;49(1):53–8.
27. Tambajong RN, Lalenoh DC, Kumaat L. Profil penderita sepsis di ICU RSUP Prof . Dr . R . D . Kandou Manado periode Desember 2014-November 2015. *J e-Clinic.* 2016;4(1):452–7.
28. Limmathurotsakul D. Causes and outcomes of sepsis in southeast Asia: a multinational multicentre cross-sectional study. *Lancet Glob Heal.* 2017;5(2):e157–67.
29. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Isaiah R, Vincent J, et al. Sepsis and septic shock. *Nat Rev Dis Prim.* 2017;2(16045):1–47.
30. Azmi ANQ. Pola Resistensi Bakteri Terhadap Antibiotik pada Pasien Sepsis di RSUP Dr M Djamil Padang Tahun 2017 (skripsi). Padang: Fakultas Farmasi Universitas Andalas; 2016
31. Andre Kalil, MD, MPH; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP M. Septic Shock. <https://emedicine.medscape.com/article/168402-overview#a4> – Diakses November 2018
32. Gotts JE, Matthay MA. Sepsis: Pathophysiology and clinical management. *BMJ.* 2016;353 :i1585.
33. Rahmawati R, Budiono U. Korelasi Antara Skor APACHE II dengan lama rawat inap pasien sepsis di ICU RSUP Dr. Kariadi Semarang (skripsi). Semarang: Fakultas Kedokteran Universitas Diponegoro; 2013
34. Arefian H, Heublein S, Scherag A, Brunkhorst FM, Younis MZ, Moerer O, et al. Hospital-related cost of sepsis: A systematic review. *J Infect.* 2017;74(2):107–17.

35. Purwanti OS, Sinuraya RK, Pradipta IS, Abdulah R. Cost Minimization Analysis of Antibiotic Used by Sepsis Patients at a Hospital in Bandung. *J Farm Klin Indones*. 2013;2(1):18–27.
36. Iman MN. Aktivitas Antibakteri Ekstrak Metanol Bunga Pepaya Jantan (*Carica papaya L*) Terhadap *Escherichia coli* dan *Staphylococcus aureus* Multiresisten Antibiotik (skripsi). Surakarta: Surakarta: Universitas Muhammadiyah Surakarta; 2009.
37. Clardy J, Fischbach M, Currie C. The natural history of antibiotics. *Curr Biol*. 2010;19(11):1–8.
38. Moore D. Antibiotic Classification & Mechanism. <https://www.orthobullets.com/basic-science/9059/antibiotic-drugs>. Diakses November 2018.
39. Kementerian Kesehatan RI. Pedoman Umum Penggunaan Antibiotik. 2011.
40. Liang SY, Kumar A, Sciences H. Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance. 2016;17(7):1–23.
41. Remington JP, Allen L V, editor. Remington: The Science and Practice of Pharmacy. 22nd ed. Philadelphia: Pharmaceutical Press; 2013.
42. Kumar S, Baldi A. Pharmacoeconomics: Principles, Methods and Economic Evaluation of Drug Therapies. *PhTechMed*. 2013;2(5):362–9.
43. Ernst FR, Levy H, Qualy RL. Simplified pharmacoeconomics of critical care and severe sepsis. *J Intensive Care Med*. 2007;22(5):283–93.
44. Khoiriyah SD, Lestari K. Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia. *Farmaka*. 2013;16(3):1–15.
45. Evaluating the cost of pharmaceuticals. In: Management Sciences for Health and World Health Organization. Drug and Therapeutics Committee Training Course. Arlington: Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program; 2007.
46. Kementerian Kesehatan RI. Profil Kesehatan Indonesia Tahun 2009. 2009.
47. The NB Provincial Health Authorities Anti-infective Stewardship Committee. Antimicrobial Treatment Guidelines for Common Infections. 2016.

48. Maloney K, Chaiken BP. an overview of outcomes research and measurement.pdf. *J Healthc Qual.* 1999;21(6):4–10.
49. Katu S, Suwanto S, Pohan HT, Abdullah M. Faktor-Faktor yang Mempengaruhi Keberhasilan Terapi Antibiotik Empirik pada Pasien Sepsis Berat dan Syok Sepsis di Bangsal Rawat Inap Penyakit Dalam Rumah Sakit Cipto Mangunkusumo. *J Penyakit Dalam Indones.* 2015;2(2):96–106.
50. Lee C, Yo C, Lee MG, Tsai K, Lee S, Chen Y, et al. Adult sepsis - A nationwide study of trends and outcomes in a population of 23 million people. *J Infect.* 2017;(7).
51. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Cardiovascular and immunological aspects. *Virulence* 2014;5(1):12–9.
52. Nasir N, Jamil B, Siddiqui S, Talat N, Khan FA, Hussain R. Mortality in Sepsis and its relationship with Gender. *Pak J Med Sci.* 2015;31(5):1201–6.
53. Alan E. Jones, MD, Stephen Trzeciak, MD, MPH, and Jeffrey A. Kline M. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. *Crit Care Med* 2010;37(5):1649–54.
54. Putri Y. Faktor Risiko Sepsis pada Pasien Dewasa di RSUP Dr. Kariadi (skripsi). *Jurnal Media Medika Muda.* Semarang: Universitas Diponegoro; 2014.
55. Rahayu C, S. Purwanti O, K. Sinuraya R, P. Destiani D. Analisis Efektivitas Biaya Penggunaan Antibiotik Pasien Sepsis di Rumah Sakit di Bandung. *Farm J Indones Klin.* 2013;2(2):77–84.
56. Starr ME, Saito H. Sepsis in Old Age : Review of Human and Animal Studies. *Aging and Disease* 2014;5(2):126–36.
57. Zhao G, Li D, Zhao Q, Song J, Chen X, Hong G, et al. Incidence , risk factors and impact on outcomes of secondary infection in patients with septic shock : an 8-year retrospective study. *Nat Publ Gr.* 2016;64(38361):1–9.
58. Rahmawati FA. Angka Kejadian Pneumonia pada Pasien Sepsis di ICU Dr. Kariadi Semarang (skripsi). Semarang: Universitas Diponegoro; 2014.

59. Akbar I, Widjajanto E, Fathoni M, Studi P, Keperawatan M, Kedokteran F, et al. Faktor Dominan dalam Memprediksi Mortalitas Pasien dengan Sepsis di Unit Gawat Darurat. *J Kedokt Brawijaya* 2018;30(2):153–8.
60. Pradipta IS, Sodik DC, Lestari K, Parwati I, Halimah E, Diantini A, et al. Antibiotic Resistance in Sepsis Patients: Evaluation and Recommendation of Antibiotic Use. *N Am J Med Sci.* 2013;5(6):344–52.
61. Fardholi A, Inayati. Pola Kepekaan Kuman Dan Terapi Antibiotika Empiris Pada Kasus Sepsis Di Rs Pku Muhammadiyah Yogyakarta. 2017:33–41.
62. Abad CL, Kumar A. Antimicrobial Therapy of Sepsis and Septic Shock-When Are Two Drugs Better Than One?. *Crit Care Clin.* 2011;27.
63. Lie KC, Lau C, Chau NVV, West TE, Limmathurotsakul D. Utility of SOFA score, management and outcomes of sepsis in Southeast Asia : a multinational multicenter prospective observational study. *J Intensive Care.* 2018;6(9):1–8.
64. NHS England. Improving outcomes for patients with sepsis, A cross-system action plan. 2015
65. Hantrakun V, Somayaji R, Teparrukkul P, Boonsri C. Clinical epidemiology and outcomes of community acquired infection and sepsis among hospitalized patients in a resource limited setting in Northeast Thailand : A prospective observational study ( Ubon-sepsis ). *PLoS One.* 2018;13(9):1–14.
66. Menéndez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, et al. Initial management of pneumonia and sepsis: Factors associated with improved outcome. *Eur Respir J.* 2012;39(1):156–62.
67. Arefian H, Heublein S, Scherag A, Brunkhorst FM, Younis MZ, Moerer O, et al. Hospital-related cost of sepsis: A systematic review. *J Infect.* 2017;74(2):107–17.
68. Koster-Brouwer ME, Klein Klouwenberg PMC, Pasma W, Bosmans JE, van der Poll T, Bonten MJM, et al. Critical care management of severe sepsis and septic shock: A cost-analysis. *Netherlands J Crit Care.* 2016;24(3):12–8.
69. Silva E, Araujo D V. Economic and Social Burden of Severe Sepsis. In: Vincent JL (eds) *Yearbook of Intensive Care and Emergency Medicine.* Berlin: Springer. 2009.

70. ESICM 2014: The Cost of Sepsis in the ICU. 2014. <https://healthmanagement.org/c/icu/news/esicm-2014-the-cost-of-sepsis-in-the-icu>. Diakses November 2018
71. Abdullah R, Sinuraya RK, Pradipta IS. Analisis Minimalisasi Biaya Antibiotik Pasien Sepsis Salah Satu Rumah Sakit Kota Bandung. *J Farm Klin Indones*. 2013;2(1):18–27.
72. Meletis G. Carbapenem resistance : overview of the problem and future perspectives. *Ther Adv Infect Dis*. 2016;3(1):15–21.
73. Halim S V, Yulia R, Setiawan E. Penggunaan antibakteri golongan carbapenem pada pasien sepsis dewasa rawat inap sebuah rumah sakit swasta di surabaya. *J Farm Klin Indones*. 2017;6(4):267-281
74. Xin X, Jian L, Xia X, Jia B, Huang W, Li C, et al. A multicentre clinical study on the injection of ceftriaxone / sulbactam compared with cefoperazone / sulbactam in the treatment of respiratory and urinary tract infections. *Ann Clin Microbiol Antimicrob*. 2013;12(38):1–8.
75. Menteri Kesehatan RI. *Formularium Nasional*. 2013.
76. Mangi RJ, Peccerillo KM, Ryan J, Berenson C, Greco T, Thornton G, et al. Cefoperazone versus Ceftriaxone Monotherapy of Nosocomial Pneumonia. *Diagn microbiol infect dis*. 1992;15:441–7.
77. Wulandari DN. Efektivitas Penggunaan Antibiotik Ceftriaxone pada pasien pneumonia dewasa di Instalasi rawat inap RSUD dr. Moewardi Surakarta Tahun 2014-2015 (skripsi). Surakarta: Universitas Sebelas Maret; 2016.
78. Penno EC, Baird SJ, John CA. Cost-Effectiveness of Surveillance for Bloodstream Infections for Sepsis Management in Low-Resource Settings. *Am J Trop Med Hyg*. 2015;93(4):850-60
79. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia. *Scand J Infect Dis*. 1998;30:397–404.
80. Destiani DP, Milanda T, Susilawati S, Suwantika AA, Pradipta IS, Halimah E, et al. Cost-Effectiveness Analysis of Ceftazidime-Levofloxacin and Cefotaxime-Erythromycin As Empirical Antibiotic Combinations in

Respiratory Infection-Induced Sepsis. *Asian J Pharm Clin Res.* 2017;10(14):119.

81. Iroezindu M, Chima E, Isiguzo G, Mbata G, Onyedum C, Onyedibe K, et al. Sputum bacteriology and antibiotic sensitivity patterns of community-acquired pneumonia in hospitalized adult patients in Nigeria: a 5-year multicentre retrospective study. *Scand J Infect Dis.* 2014;46(12):875-87.
82. Buckman SA, Turnbull IR, Mazuski JE. Empiric Antibiotics for Sepsis. *Surg Infect.* 2018;19(2):147–54.

